Southern Europe, led by Italy and Spain, has established itself as a critical pillar of the European ADC landscape, primarily distinguished by its excellence in clinical translation and pioneering target discovery. While Northern Europe often focuses on the chemistry of the "linker" the Italian and Spanish ecosystems excel at the "ends" of the ADC: discovering novel, potent payloads and validating them in high-efficiency clinical settings.

The region is anchored by world-class clinical research hubs like the Vall d’Hebron Institute of Oncology (VHIO) in Barcelona and Nerviano Medical Sciences in Milan. Spain has carved out a unique niche in stroma-targeting ADCs and marine-derived payloads (pioneered by Pharma Mar), while Italy leads in the development of small-format antibody scaffolds (such as Philogen’s "mini-antibodies") designed for faster tumor penetration. For international giants like AstraZeneca and Gilead, Italy and Spain are indispensable hubs for Phase 1-3 clinical enrollment, offering a sophisticated hospital infrastructure that bridges the gap between laboratory innovation and patient access.